The decrease in prostate cancer screening rates was the smallest among 5 cancers studied.
The approval is supported by data from the phase 3 BEACON CRC trial in adults with BRAF V600E mutation-positive metastatic colorectal cancer with disease progression.
A comparison of data from 2 studies on peripheral neuropathy found that CRC survivors would benefit from education related to recognizing early symptoms.
The study showed no significant differences in outcomes by age.
Patients with liver metastases did not respond to checkpoint inhibitors.